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The oral antifibrotic agent, pirfenidone (PFD), 5-methyl-l-phenyl-[1H]-pyridine, is used to treat 
idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease. In trials, PFD reduces disease 
progression and decreases mortality. The most common side events of PFD are skin manifestations 
(25%), described as a photosensitivity or rash, but they are not well characterised 1. The objective of 
the present real-life study was to address the question of skin manifestations in patients treated with 
PFD for IPF. 
 
We performed a single-centre cross-sectional study of 54 patients treated with PFD for IPF (85% 
men, median age 74 years, median exposure time 11.9 months), in the Department of Pulmonology 
(Competence Centre for Rare Lung Diseases), at Rennes University Hospital (CHU), France, between 
April 2014 and January 2017. The study was approved by the CHU Ethics Committee and all patients 
signed informed consent in accordance with the principles of the Helsinki Declaration. 
 
Of the 54 patients treated with PFD, 13 (22.2%) experienced skin manifestations. All were declared to 
the Rennes Pharmacovigilance. This database showed that 12 patients had photosensitivity and one 
urticaria. Eight patients, none of whom had a history of photosensitive diseases, were assessed by a 
dermatologist (Table 1). The mean duration between starting PFD and a skin manifestation was 5.5 
months. They developed burning erythema followed by hyperpigmentation which was sharply limited 
to sun-exposed areas (bald head, face, neck, upper chest and/or dorsa of forearms and hands), where 
sunscreen has not been applied one day after UV exposure. These findings were consistent with a 
moderate phototoxic reaction. Skin biopsies performed in cases 1, 3 and 6, showed epidermal 
spongiosis with a lichenoid reaction and moderate dermal perivascular lymphocytic infiltration. 
Apoptotic keratinocytes were observed in case 1. All patients were successfully treated with topical 
corticosteroid within 8 days. Three patients discontinued PFD due to gastrointestinal disorders and 
fatigue. No patient relapsed. Other long-term medication was continued. 
 
Photobiological explorations were realized on the back of patients with an ultraviolet (UV)A lamp 
(Waldmann® 182, Reischtett, France) and a solar simulator (Dermolum UM-UW Müller Elektronik®, 
Moosinning, Germany) emitting polychromatic spectrum (95%UVA/5%UVB). Polychromatic 
minimal erythema dose (MED) was evaluated 24 hours after exposure for 5 patients tested in normal 
values. UVA MED was normal (> 20J/cm²) at baseline in all of the 3 cases evaluated. After skin 
reaction, the reactivity threshold was lower in UVA: an erythema appeared for 20J/cm² 24 hours after 
exposure in 6 of 6 patients tested. We examined 5 patients using PFD photopatches (contents of 
Esbriet® 267mg capsule, 30% petrolatum). The irradiated site of 4 patients was positive one and two 
days after UVA-irradiation (7J/cm²) with 3 having strong crescendo eczematous reaction. The non-
irradiated patch showed no reaction.  
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Porphyrins in the blood and urine were assayed at PFD introduction and during the skin 
manifestations in 3 patients: all were normal. The niacin values of 2 of the 3 patients tested were 
initially low and were not significantly altered after photosensitivity.  
 
To our knowledge, this study represents the largest documented series of PFD photosensitivity 
because such sporadic case reports have been only published. 2-6 One fifth of our patients were 
photosensitive, consistent with data from PFD safety analysis 1. Our patients seen by a dermatologist 
had clinical features of phototoxicity. All were treated with maximum dose of PFD. Photobiochemical 
studies demonstrated the phototoxicity of PFD 7, confirmed by clinical reported cases. 2, 3 Our results 
do not indicate that phototoxicity is linked to the metabolism of porphyrins or niacin. In patients with 
low niacin serum concentration, we did not assess their diets and found no drug-induced niacin 
deficiency.  
 
Furthermore, three cases of PFD photoallergic reaction were recently published. 4, 6 Photoallergic 
dermatitis is characterised by eczematous eruption starting in light-exposed areas and later spreading 
to covered sites. This clinical presentation was not found in our patients, but histology (lichenoid 
pattern) and photopatch testing (crescendo eczematous reaction) were in accordance with 
photoallergic features. Therefore, we believe the mechanism underlying the PFD photosensitivity 
involves a combination of photoallergic and phototoxic effects. 
 
Our photobiological explorations showed that UVA irradiation influenced PFD photosensitivity, as in 
most drug-induced photosensitization. 8 Very few cases with PFD phototesting have been reported. 3, 6 
In one case, UVA and UVB MEDs were decreased. 3 Lastly, only one patient had UVA PFD patch 
and was positive 6, as in most of our cases tested.  
 
The great photosensitivity of PFD requires optimal management including photoprotection and a 
close collaboration between dermatologists, pulmonologists and general practitioners.  
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Table 1. Clinical, biological, and photobiological characteristics of skin manifestations for patients 
with idiopathic pulmonary fibrosis treated with pirfenidone and seen by a dermatologist. 
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Table 1. Clinical, biological and photobiological characteristics of skin manifestations for patients with idiopathic pulmonary fibrosis treated with pirfenidone and seen by a 
dermatologist. 
 
Case Age 
(y) 
Sex Phototype 
(Fitzpatrick
’s 
classificatio
n) 
Long-term therapy* Type of skin side 
event and 
dermatological 
examination 
Period of use 
PFD before 
skin event, in 
months 
PFD dose on 
onset of 
photosensitivity 
(mg/day) 
Treatment Polychromatic 
MED (Normal > 
1 J/cm²) before/ 
during PFD 
treatment  
UVA phototest 
before PFD 
starting (20 
J/cm²)** 
UVA 
phototest 
during skin 
reaction (20 
J/cm²)** 
PFD 
patch 
test  
Niacin dosage 
before/during 
PFD treatment 
(Normal > 38 
µmol/L) 
Porphyrins 
dosage in 
blood and 
urine 
before/during 
PFD 
treatment 
1 74 M III Lansoprazole, irbesartan, 
rosuvastatin 
Phototoxicity 
(Grade II) on head 
and dorsa of hands 
4 2403 Topical 
corticosteroids, 
photoprotective 
measures,  
PFD continued 
ND ND ND ND ND ND 
2 68 M III Lansoprazole, prednisone, 
simvastatin, valsartan, 
budesonide/formoterol 
Phototoxicity 
(Grade II) on dorsa of 
hands 
10 2403 Photoprotective 
measures, 
PFD continued  
Normal: 1.5/1.25 - Erythema NI : - 
UVA: + 
40/52 Normal/ 
Normal  
3 77 F II Amlodipine, salbutamol, 
indacaterol/glycopyrronium
, alendronic acid, 
metoclopramide 
Phototoxicity 
(Grade II) on 
forehead and dorsa of 
hands 
3 2403 High potent topical 
corticosteroids, 
photoprotective 
measures. 
Decrease PFD dose 
(1602mg) due to 
digestive disorders 
ND - Erythema ND 22/31 Normal/ 
Normal  
4 68 M II Lercanidipine, olmesartan, 
fenofibrate, lansoprazole 
Phototoxicity 
(Grade II) on head 
and neck 
11 2403 Photoprotective 
measures 
PFD continued 
ND/Normal: 1.25  ND Erythema NI :- 
UVA :- 
ND/35 ND/Normal  
5 75 M II Ramipril/hydrochlorothiazi
de, acetylsalicylate, 
bosiprolol, lansoprazole, 
rosuvastatin, amlodipine 
Phototoxicity 
(Grade II) on head, 
neck, scalp, ears, and 
dorsum of hands  
5 2403 Topical 
corticosteroids,PFD 
discontinued 
ND/Normal: 1.75  - Erythema NI: -
UVA: ++ 
22/51 Normal/ 
Normal  
6 79 M II Acetylsalicylate, 
hydrocortisone, 
levothyroxine, testostérone, 
bisoprolol, atorvastatin, 
ramipril, lansoprazole 
Phototoxicity 
(Grade II) on head, 
neck and dorsa of 
hands  
2 2403 Topical 
corticosteroids, 
PFD discontinued 
ND/Normal: 1.75  ND Erythema NI : - 
UVA : ++ 
ND / 35 ND/ Normal  
7 68 F II Pantoprazole, rosuvastatin, 
paroxetine, domperidone, 
lebrikizumab 
Phototoxicity 
(Grade II) on neck, 
upper chest, dorsa of 
forearms and hands 
7 2403 Topical 
corticosteroids, 
photoprotective 
measures, 
PFD continued 
ND/Normal: 1.75  ND Erythema NI : -
UVA : ++ 
ND / 42 ND/Normal  
8 66 M II None Phototoxicity 
(Grade II) on 
head and dorsa of 
hands 
2 2403 Topical 
corticosteroids, 
PFD discontinued 
ND ND ND ND ND ND 
 
y: years. M: male. F: female. Grade II: according to the Common Terminology Criteria Adverse Event (CTCAE). PFD: pirfenidone. MED: minimal erythema dose. ND: not done. NI: non-irradiated PFD patch test. - : 
negative reaction. + or ++ : positive reaction according International Contact Dermatitis Research Group (ICDRG) system.  
* More than six months
** In our laboratory, the normal values for UVA MED were 21-80 J/cm2. MED was considered to be pathological after positive reaction in response to 20J/cm², 24 hours after UVA exposure. 
 
 
